MedPath

Study of effects of Naltrexone treatment in alcohol dependent patients and influence by genotypes.Naltrexone is an FDA approved medication for treating alcohol dependence

Phase 4
Not yet recruiting
Conditions
Health Condition 1: null- Alcohol Dependence Syndrome
Registration Number
CTRI/2017/12/010848
Lead Sponsor
avina Suresh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.ICD 10 criteria for alcohol use disorder.

2.Alcohol use disorder male subjects between the age group 18 to 60 years.

3.Abstinence from alcohol and other substances for 3-7 days.

4.Ability to provide informed consent.

5. One or more relatives or significant others who are willing to encourage medication therapy, adherence and provide follow-up information if contacted by research staff.

Exclusion Criteria

1.Major psychiatric disorder (i.e, schizophrenia, bipolar disorder, seizure disorder, alcohol induced psychotic disorder or dementia).

2.Advanced neurological, cardiovascular, renal, or hepatic disease; active tuberculosis or current febrile illness.

3.AIDS defining illness.

4.Significant laboratory abnormality (alanine aminotransferase/aspartate aminotransferase [ALT/AST] levels of greater than 5 times the top reference limit).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.